Zhao D, Mambetsariev I, Li H, et al. - In patients suffering from advanced non-small cell lung cancer (NSCLC), researchers determined molecular features related to the efficacy of immune checkpoint inhibitors (ICIs). They retrospectively identified all patients with advanced stage NSCLC at City of Hope that were treated with ICIs (pembrolizumab, nivolumab, atezolizumab, and durvalumab). This study included 346 NSCLC patients. In univariate and multivariate analysis, experts identified a link between overall survival (OS) and programmed death-ligand 1 level ≥ 50%, EGFR, and TET2. The median OS was not reached [NR] for the 12 patients with genomic alterations (GAs) in TET2 (12/108, 11%) vs 11.5 months in TET2 negative patients (98/108, 89%). The clinical as well as molecular characteristics of NSCLC patients managed with ICIs were reported in this study. The observed link of GAs in TET2 with longer OS as well as its mutual exclusivity with FANCA GAs afford a better understanding for the development of new treatment strategies to provide better results with ICIs in NSCLC.